Allogene Therapeutics, Inc. (ALLO) Reports In-Line Q2 EPS

Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q2 EPS of ($0.35), in-line with the analyst estimate of ($0.35).

For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.

You May Also Be Interested In

• Apollo Global Management (APO) call put ratio 1 call to 6.8 puts a focus on a spreader of 9K contracts January 95 and 135 puts
• Jefferies Starts Louisiana-Pacific Corp (LPX) at Buy
• Dataram (DRAM) call put ratio 1.4 calls to 1 put into Korean market weakness and Micron (MU) quarter results